Borody Thomas J, Paramsothy Sudarshan, Agrawal Gaurav
Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock, Sydney, NSW 2046, Australia.
Curr Gastroenterol Rep. 2013 Aug;15(8):337. doi: 10.1007/s11894-013-0337-1.
Fecal microbiota transplantation (FMT) has attracted great interest in recent years, largely due to the global Clostridium difficile infection (CDI) epidemic and major advances in metagenomic sequencing of the gastrointestinal (GI) microbiota, with growing understanding of its structure and function. FMT is now recommended as the most effective therapy for relapsing CDI and, with further refinement, may even be used in "first-time" CDI. There is interest also in other conditions related to GI dysbiosis--for example, inflammatory bowel disease, irritable bowel syndrome, obesity, and diabetes mellitus--although quality evidence is at present lacking. A few trials are now underway in FMT for ulcerative colitis. Many unanswered questions remain, including FMT methodology--for example, optimal route of administration, what makes a "good donor," safety issues, and long-term effects of FMT.
近年来，粪便微生物群移植（FMT）引起了极大的关注，这主要归因于全球艰难梭菌感染（CDI）的流行以及胃肠道（GI）微生物群宏基因组测序的重大进展，人们对其结构和功能的认识不断加深。目前，FMT被推荐为复发性CDI最有效的治疗方法，随着进一步完善，甚至可能用于“首次”CDI。人们也对与胃肠道生态失调相关的其他病症感兴趣，例如炎症性肠病、肠易激综合征、肥胖症和糖尿病，尽管目前缺乏高质量的证据。目前有几项关于FMT治疗溃疡性结肠炎的试验正在进行。许多问题仍未得到解答，包括FMT方法，例如最佳给药途径、什么样的供体是“优质供体”、安全问题以及FMT的长期影响。
